Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its stake in Sana Biotechnology, Inc. (NASDAQ:SANA) by 0.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,056,512 shares of the company’s stock after acquiring an additional 8,666 shares during the period. Charles Schwab Investment Management Inc. owned 0.47% of Sana Biotechnology worth $1,722,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Barclays PLC boosted its holdings in shares of Sana Biotechnology by 126.6% in the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock valued at $1,325,000 after acquiring an additional 178,179 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Sana Biotechnology in the fourth quarter valued at about $239,000. FMR LLC boosted its holdings in Sana Biotechnology by 16.3% in the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after purchasing an additional 4,438,949 shares in the last quarter. Geode Capital Management LLC increased its position in Sana Biotechnology by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after purchasing an additional 276,055 shares during the period. Finally, Stifel Financial Corp purchased a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $43,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Sana Biotechnology in a research note on Tuesday, March 18th. Citizens Jmp raised shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research note on Tuesday, March 18th. TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, Jefferies Financial Group began coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They set a “buy” rating and a $7.00 price objective on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Insider Transactions at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the sale, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 31.10% of the company’s stock.

Sana Biotechnology Stock Down 7.3 %

Shares of SANA stock opened at $1.71 on Friday. The stock has a market cap of $384.79 million, a P/E ratio of -1.22 and a beta of 1.63. Sana Biotechnology, Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $10.50. The business has a fifty day simple moving average of $2.80 and a 200-day simple moving average of $3.03.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. On average, sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.